Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

The Lead

Amid ALS Mania, Possible Drug Target Spotted

August 21, 2014 3:02 pm | by Cynthia Fox, Science Editor | Articles | Comments

As, all around them, everyone from Derek Jeter to the Kennedy family was dousing themselves in ice water for the ALS “Ice Bucket Challenge,” Harvard researchers announced last week they may have found an ALS therapy. Read more...      

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

AstraZeneca, Illumina Partner on Gene Sequencing

August 21, 2014 4:12 pm | News | Comments

AstraZeneca announced that it has entered into a collaboration with gene sequencing company, Illumina Inc., to develop its next generation sequencing platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio. Read more…

TOPICS:

FDA Clears Eliquis for New Use Against Blood Clots

August 21, 2014 3:28 pm | by The Associated Press | News | Comments

Bristol-Myers Squibb and Pfizer said Thursday that federal regulators have expanded approval of their blood thinner Eliquis to treat two types of dangerous blood clots. Read more...                    

TOPICS:

New Hydrocodone Testrictions to Take Effect

August 21, 2014 1:00 pm | News | Comments

The federal government is finalizing new restrictions on hundreds of medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the U.S. Read more...            

TOPICS:
Advertisement

Botox Injections Slow Growth of Stomach Tumors

August 21, 2014 1:00 pm | News | Comments

New research shows that nerves may play a critical role in stomach cancer growth and that blocking nerve signals using Botox (onabotulinumtoxinA) could be an effective treatment for the disease. Read more...             

TOPICS:

Both American Ebola Patients Discharged from Hospital

August 21, 2014 1:00 pm | by Jeff Martin and Katie Foody | News | Comments

After nearly three weeks of treatment, the two American aid workers who were infected with the deadly Ebola virus in Africa have been discharged from an Atlanta hospital, officials said Thursday. Read more...            

TOPICS:

Emergent, MorphoSys Collaborate on Prostate Cancer Drug

August 21, 2014 11:39 am | News | Comments

Emergent BioSolutions and MorphoSys announced an agreement for the joint development and commercialization of Emergent’s preclinical bi-specific antibody, ES414, targeting prostate cancer, under the terms of which Emergent will receive an upfront payment of US$20 million and milestone payments of up to US$163 million. Read more...

TOPICS:

Eisai Submits EU Marketing Authorization for Anti-Epileptic

August 21, 2014 11:34 am | News | Comments

Eisai has submitted a Marketing Authorization Application to the European Commission for its first-in-class anti-epileptic drug (AED) Fycompa (perampanel) as an adjunctive treatment of primary generalized tonic-clonic seizures (PGTC). Read more...

TOPICS:

Ebola: Slum Calm; Aid Worker Recovers

August 21, 2014 11:12 am | by Jonathan Paye-Layleh, Associated Press | News | Comments

Calm returned Thursday to a slum in the Liberian capital that was sealed off in the government's attempt to halt the spread of Ebola, a day after clashes erupted between residents and security forces, and in the United States, an aid worker who was infected in Liberia has recovered. Read more...

TOPICS:
Advertisement

Novan’s Topical Treatment Shows Efficacy Against Drug-resistant Bugs

August 20, 2014 2:29 pm | News | Comments

Novan Therapeutics announced that the company’s Nitricil platform technology has been shown to be efficacious against several of the most multi-drug resistant pathogens plaguing civilian and military health care providers across the globe. Read more...

TOPICS:

Novartis Licenses Candidate Compounds to TB Alliance

August 20, 2014 2:17 pm | News | Comments

Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds to fight tuberculosis (TB). Read more...                    

TOPICS:

New Vaccine Promising Weapon Against TB, Leprosy

August 20, 2014 2:09 pm | News | Comments

The currently available century-old vaccine Bacille Calmette-Guerin, or BCG, provides only partial protection against both tuberculosis and leprosy. Now, researchers may have found a stronger weapon against both diseases. Read more...     

TOPICS:

Drug Candidate Blocks 'Chili-pepper Receptor'

August 20, 2014 1:59 pm | News | Comments

As anyone who has bitten into a chili pepper knows, its burning spicinesscan be intolerable. Scientists exploring the chili pepper’s effect are using their findings to develop a new drug candidate for many kinds of pain. Read more...     

TOPICS:

FDA Approves New Drug for Gaucher's Disease

August 20, 2014 1:45 pm | News | Comments

The FDA approved a new capsule-based drug to treat Gaucher's disease. Regulators approved the new drug, Cerdelga, for patients with the Type 1 form of the rare genetic disorder. Read more...                 

TOPICS:

Rating U.S. Drug Development Programs

August 20, 2014 11:10 am | by Chris Plaford, CFA, Chief Executive Officer, Claravant Analytics LLC | Articles | Comments

According to industry estimates, the majority of drugs in development will never make it to FDA approval. While a lack of efficacy is often a key factor, many clinical programs are derailed due to avoidable setbacks that can cause delays and significantly increase costs. Read more...

TOPICS:

CEL-SCI Expands Head, Neck Cancer Trial in North America

August 20, 2014 10:47 am | News | Comments

CEL-SCI Corporation announced its Phase 3 Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine has added Centre Hospitalier Universitaire de Québec’s L’Hotel Dieu de Quebec to its growing number of clinical sites in North America. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading